{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T17:38:38Z","timestamp":1790444318756,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,9,27]],"date-time":"2016-09-27T00:00:00Z","timestamp":1474934400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","ajconline.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.amjcard.2016.09.010","type":"journal-article","created":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T10:25:18Z","timestamp":1475317518000},"page":"40-46","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":123,"title":["Effect of Alirocumab on Lipoprotein(a) Over \u22651.5\u00a0Years (from the Phase 3 ODYSSEY Program)"],"prefix":"10.1016","volume":"119","author":[{"given":"Daniel","family":"Gaudet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald F.","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer G.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Minini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Sasiela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Edelberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Louie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick J.","family":"Raal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2016.09.010_bib1","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1210\/jc.2015-1520","article-title":"Alirocumab as add-on to atorvastatin versus other lipid treatment strategies: ODYSSEY OPTIONS I randomized trial","volume":"100","author":"Bays","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.amjcard.2016.09.010_bib2","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/eurheartj\/ehv028","article-title":"Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial","volume":"36","author":"Cannon","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2016.09.010_bib3","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.atherosclerosis.2015.11.010","article-title":"Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: the ODYSSEY OPTIONS II randomized trial","volume":"244","author":"Farnier","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.amjcard.2016.09.010_bib4","first-page":"2996","article-title":"ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia","volume":"36","author":"Kastelein","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2016.09.010_bib5","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s10557-016-6685-y","article-title":"Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia and LDL-C of 160 mg\/dL or higher","volume":"30","author":"Ginsberg","year":"2016","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.amjcard.2016.09.010_bib6","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.ahj.2015.03.004","article-title":"Efficacy and safety of the proprotein convertase subtilisin\/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study","volume":"169","author":"Kereiakes","year":"2015","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2016.09.010_bib7","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jacl.2015.08.006","article-title":"Efficacy and safety of alirocumab versus ezetimibe in statin-intolerant patients, with a statin-re-challenge arm: the ODYSSEY ALTERNATIVE randomized trial","volume":"9","author":"Moriarty","year":"2015","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.amjcard.2016.09.010_bib8","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjcard.2016.09.010_bib9","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ijcard.2014.06.049","article-title":"Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial","volume":"176","author":"Roth","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.amjcard.2016.09.010_bib10","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.amjcard.2014.05.060","article-title":"Effect of alirocumab, a monoclonal proprotein convertase subtilisin\/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials)","volume":"114","author":"Gaudet","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2016.09.010_bib11","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Erqou","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2016.09.010_bib12","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","article-title":"Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population","volume":"63","author":"Kamstrup","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2016.09.010_bib13","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jacl.2015.02.003","article-title":"National lipid association recommendations for patient-centered management of dyslipidemia: part 1\u2013full report","volume":"9","author":"Jacobson","year":"2015","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.amjcard.2016.09.010_bib14","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein(a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2016.09.010_bib15","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/MOL.0000000000000126","article-title":"Latest developments in the treatment of lipoprotein (a)","volume":"25","author":"Bos","year":"2014","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.amjcard.2016.09.010_bib16","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.atherosclerosissup.2015.02.039","article-title":"Lipoprotein(a)\u2013An independent causal risk factor for cardiovascular disease and current therapeutic options","volume":"18","author":"Kasssner","year":"2015","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.amjcard.2016.09.010_bib17","doi-asserted-by":"crossref","first-page":"3478a","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2016.09.010_bib18","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nrd3699","article-title":"The biology and therapeutic targeting of the proprotein convertases","volume":"11","author":"Seidah","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.amjcard.2016.09.010_bib19","doi-asserted-by":"crossref","first-page":"11649","DOI":"10.1074\/jbc.M114.611988","article-title":"Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin\/kexin type 9 through the low density lipoprotein receptor","volume":"290","author":"Romagnuolo","year":"2015","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.amjcard.2016.09.010_bib20","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1161\/CIRCULATIONAHA.113.004678","article-title":"Effect of the proprotein convertase subtilisin\/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia","volume":"128","author":"Stein","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2016.09.010_bib21","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jacl.2016.03.099","article-title":"Evaluating the roles of PCSK9 and specific receptors in lipoprotein(a) catabolism","volume":"10","author":"Koschinsky","year":"2016","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.amjcard.2016.09.010_bib22","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s11789-015-0075-z","article-title":"Lipoprotein(a)-clinical aspects and future challenges","volume":"10","author":"Kurt","year":"2015","journal-title":"Clin Res Cardiol Suppl"},{"key":"10.1016\/j.amjcard.2016.09.010_bib23","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.cca.2014.07.008","article-title":"PCSK9 and lipid lowering drugs","volume":"437","author":"Guo","year":"2014","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.amjcard.2016.09.010_bib24","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.amjcard.2014.10.018","article-title":"Effects of niacin, statin, and fenofibrate on circulating proprotein convertase subtilisin\/kexin type 9 levels in patients with dyslipidemia","volume":"115","author":"Khera","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2016.09.010_bib25","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1194\/jlr.P065334","article-title":"PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role","volume":"57","author":"Raal","year":"2016","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.amjcard.2016.09.010_bib26","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1253\/circj.CJ-16-0387","article-title":"Efficacy and safety of alirocumab in Japanese patients with heterozygous familial hypercholesterolemia or at high cardiovascular risk with hypercholesterolemia not adequately controlled with statins- ODYSSEY Japan randomized controlled trial","volume":"80","author":"Teramoto","year":"2016","journal-title":"Circ J"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914916315685?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914916315685?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T20:59:31Z","timestamp":1536353971000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914916315685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S0002914916315685"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2016.09.010","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726912833.793526528","asserted-by":"object"}]},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of Alirocumab on Lipoprotein(a) Over \u22651.5\u00a0Years (from the Phase 3 ODYSSEY Program)","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2016.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}